MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy

Sharon Elad; Karis Kin Fong Cheng; Rajesh V. Lalla; Noam Yarom; Catherine Hong; Richard M. Logan; Joanne Bowen; Rachel Gibson; Deborah P. Saunders; Yehuda Zadik; Anura Ariyawardana; Maria Elvira Correa; Vinisha Ranna; Paolo Bossi; Praveen Arany; Abdul Rahman Al-Azri; Nicole Blijlevens; Allan Hovan; Eduardo Fregnani; Janet Fulton; Luiz Alcino Gueiros; Tanya Rouleau; Janet K. Coller; Noor Al-Dasooqi; Hannah Wardill; Suzanne Ameringer; Héliton Spindola Antunes; Emma H. Bateman; Kivanc Bektas; René Jean Bensadoun; K. Ten Bohmer; Norman Brito-Dellan; Daniel Castillo; Karen Chiang; Charlotte de Mooij; June Eilers; Joel Epstein; Dimitra Galiti; Jane M. Fall-Dickson; Margherita Gobbo; Hanan Issa Hazboun; Siri Beier Jensen; Jorgen Johansen; Jamie Joy; K. Joy; Abhishek Kandwal; Tomoko Kataoka; Dorothy Keefe; Charles L. Loprinzi; Rachel Lubart; Anna Skripnik Lucas; Alessandra Majorana; Bronwen Mayo; Charlotte de Mooij; Takehiko Mori; Raj G. Nair; Narmin Nasr; Ourania Nicolatou-Galitis; Giulia Ottaviani; Cesar Migliorati; Monica Pentenero; Lorraine Porcello; Douglas Peterson; Carin Potting; Judith Raber-Durlacher; Ysabella Z.A. van Sebille; Yoshihiko Soga; Stephen Sonis; Andrea M. Stringer; Daniel Thorpe; Vanessa Tilly; Wim Tissing; Juan J. Toro; Nathaniel Simon Treister; Anusha Vaddi; Dianna Weikel; Marianne van de Wetering; Eyal Zur

doi:10.1002/cncr.33100

MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy

Sharon Elad^*
, Karis Kin Fong Cheng
, Rajesh V. Lalla
, Noam Yarom
, Catherine Hong
, Richard M. Logan
, Joanne Bowen
, Rachel Gibson
, Deborah P. Saunders
, Yehuda Zadik
, Anura Ariyawardana
, Maria Elvira Correa
, Vinisha Ranna
, Paolo Bossi
, Praveen Arany
, Abdul Rahman Al-Azri
, Nicole Blijlevens
, Allan Hovan
, Eduardo Fregnani
, Janet Fulton

Luiz Alcino Gueiros, Tanya Rouleau, Janet K. Coller, Noor Al-Dasooqi, Hannah Wardill, Suzanne Ameringer, Héliton Spindola Antunes, Emma H. Bateman, Kivanc Bektas, René Jean Bensadoun, K. Ten Bohmer, Norman Brito-Dellan, Daniel Castillo, Karen Chiang, Charlotte de Mooij, June Eilers, Joel Epstein, Dimitra Galiti, Jane M. Fall-Dickson, Margherita Gobbo, Hanan Issa Hazboun, Siri Beier Jensen, Jorgen Johansen, Jamie Joy, K. Joy, Abhishek Kandwal, Tomoko Kataoka, Dorothy Keefe, Charles L. Loprinzi, Rachel Lubart, Anna Skripnik Lucas, Alessandra Majorana, Bronwen Mayo, Charlotte de Mooij, Takehiko Mori, Raj G. Nair, Narmin Nasr, Ourania Nicolatou-Galitis, Giulia Ottaviani, Cesar Migliorati, Monica Pentenero, Lorraine Porcello, Douglas Peterson, Carin Potting, Judith Raber-Durlacher, Ysabella Z.A. van Sebille, Yoshihiko Soga, Stephen Sonis, Andrea M. Stringer, Daniel Thorpe, Vanessa Tilly, Wim Tissing, Juan J. Toro, Nathaniel Simon Treister, Anusha Vaddi, Dianna Weikel, Marianne van de Wetering, Eyal Zur

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

677 Scopus citations

Abstract

Background: Mucositis is a significant toxicity of cancer therapy with numerous systemic sequelae. The goal of this systematic review was to update the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO) Clinical Practice Guidelines for the management of mucositis. Methods: The literature was reviewed systematically to identify interventions for mucositis. Studies were rated according to the presence of major and minor flaws according to previously published criteria. The body of evidence for each intervention and in each treatment setting was assigned a level of evidence based on previously published criteria. Guidelines were developed based on the level of evidence, with 3 possible guideline determinations: recommendation, suggestion, or no guideline possible. Results: The guideline covers evidence from 1197 publications related to oral or gastrointestinal mucositis. Thirteen new guidelines were developed for or against the use of various interventions in specific treatment settings, and 11 previous guidelines were confirmed after aa review of new evidence. Thirteen previously established guidelines were carried over because there was no new evidence for these interventions. Conclusions: The updated MASCC/ISOO Clinical Practice Guidelines for mucositis provide professional health caregivers with a clinical setting-specific, evidence-based tool to help with the management of mucositis in patients who have cancer.

Original language	English
Pages (from-to)	4423-4431
Number of pages	9
Journal	Cancer
Volume	126
Issue number	19
DOIs	https://doi.org/10.1002/cncr.33100
State	Published - 1 Oct 2020

Bibliographical note

Funding Information:
According to Multinational Association of Supportive Care in Cancer (MASCC) guidelines policy, employees of commercial entities were not eligible to serve on this MASCC Guidelines Panel. Sharon Elad reports consultation fees from Falk Pharma, outside the submitted work. Rajesh V. Lalla reports institutional research support from Novartis, Oragenics, and Sucampo Pharma, outside the submitted work; grants and personal fees from Galera Therapeutics, outside the submitted work; personal fees from Alira Health, Colgate Oral Pharmaceuticals, Eagle Pharma, Enlivity, Ingalfarma SA, Meiji Seika Pharma, Monopar Therapeutics, Mundipharma, and Sucampo Pharma, outside the submitted work; stock ownership in Logic Biosciences; and has a patent pending (WO 2019/217536 A2; University of Connecticut, applicant). Deborah P. Saunders reports institutional research support from Galera Therapeutics. Paolo Bossi reports personal fees from Merck Serono, Roche, Sanofi, Merck Sharp & Dohme, Sun Pharma, AstraZeneca, Kyowa Hakko Kyrin, AstraZeneca, Bristol‐Myers Squibb, Helsinn, and Glaxo‐Smith‐Kline, outside the submitted work. The remaining authors made no disclosures.

Publisher Copyright:
© 2020 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Multinational Association of Supportive Care in Cancer and International Society for Oral Oncology (MASCC/ISOO)
cancer
gastrointestinal
guidelines
mucositis
oral

Access to Document

10.1002/cncr.33100

Cite this

Elad, S., Cheng, K. K. F., Lalla, R. V., Yarom, N., Hong, C., Logan, R. M., Bowen, J., Gibson, R., Saunders, D. P., Zadik, Y., Ariyawardana, A., Correa, M. E., Ranna, V., Bossi, P., Arany, P., Al-Azri, A. R., Blijlevens, N., Hovan, A., Fregnani, E., ... Zur, E. (2020). MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer, 126(19), 4423-4431. https://doi.org/10.1002/cncr.33100

@article{a34577c451274a80a514c7b03a775e83,

title = "MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy",

abstract = "Background: Mucositis is a significant toxicity of cancer therapy with numerous systemic sequelae. The goal of this systematic review was to update the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO) Clinical Practice Guidelines for the management of mucositis. Methods: The literature was reviewed systematically to identify interventions for mucositis. Studies were rated according to the presence of major and minor flaws according to previously published criteria. The body of evidence for each intervention and in each treatment setting was assigned a level of evidence based on previously published criteria. Guidelines were developed based on the level of evidence, with 3 possible guideline determinations: recommendation, suggestion, or no guideline possible. Results: The guideline covers evidence from 1197 publications related to oral or gastrointestinal mucositis. Thirteen new guidelines were developed for or against the use of various interventions in specific treatment settings, and 11 previous guidelines were confirmed after aa review of new evidence. Thirteen previously established guidelines were carried over because there was no new evidence for these interventions. Conclusions: The updated MASCC/ISOO Clinical Practice Guidelines for mucositis provide professional health caregivers with a clinical setting-specific, evidence-based tool to help with the management of mucositis in patients who have cancer.",

keywords = "Multinational Association of Supportive Care in Cancer and International Society for Oral Oncology (MASCC/ISOO), cancer, gastrointestinal, guidelines, mucositis, oral",

author = "Sharon Elad and Cheng, \{Karis Kin Fong\} and Lalla, \{Rajesh V.\} and Noam Yarom and Catherine Hong and Logan, \{Richard M.\} and Joanne Bowen and Rachel Gibson and Saunders, \{Deborah P.\} and Yehuda Zadik and Anura Ariyawardana and Correa, \{Maria Elvira\} and Vinisha Ranna and Paolo Bossi and Praveen Arany and Al-Azri, \{Abdul Rahman\} and Nicole Blijlevens and Allan Hovan and Eduardo Fregnani and Janet Fulton and Gueiros, \{Luiz Alcino\} and Tanya Rouleau and Coller, \{Janet K.\} and Noor Al-Dasooqi and Hannah Wardill and Suzanne Ameringer and Antunes, \{H{\'e}liton Spindola\} and Bateman, \{Emma H.\} and Kivanc Bektas and Bensadoun, \{Ren{\'e} Jean\} and \{Ten Bohmer\}, K. and Norman Brito-Dellan and Daniel Castillo and Karen Chiang and \{de Mooij\}, Charlotte and June Eilers and Joel Epstein and Dimitra Galiti and Fall-Dickson, \{Jane M.\} and Margherita Gobbo and \{Issa Hazboun\}, Hanan and Jensen, \{Siri Beier\} and Jorgen Johansen and Jamie Joy and K. Joy and Abhishek Kandwal and Tomoko Kataoka and Dorothy Keefe and Loprinzi, \{Charles L.\} and Rachel Lubart and \{Skripnik Lucas\}, Anna and Alessandra Majorana and Bronwen Mayo and \{de Mooij\}, Charlotte and Takehiko Mori and Nair, \{Raj G.\} and Narmin Nasr and Ourania Nicolatou-Galitis and Giulia Ottaviani and Cesar Migliorati and Monica Pentenero and Lorraine Porcello and Douglas Peterson and Carin Potting and Judith Raber-Durlacher and \{van Sebille\}, \{Ysabella Z.A.\} and Yoshihiko Soga and Stephen Sonis and Stringer, \{Andrea M.\} and Daniel Thorpe and Vanessa Tilly and Wim Tissing and Toro, \{Juan J.\} and Treister, \{Nathaniel Simon\} and Anusha Vaddi and Dianna Weikel and \{van de Wetering\}, Marianne and Eyal Zur",

note = "Publisher Copyright: {\textcopyright} 2020 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.",

year = "2020",

month = oct,

day = "1",

doi = "10.1002/cncr.33100",

language = "אנגלית",

volume = "126",

pages = "4423--4431",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc.",

number = "19",

}

Elad, S, Cheng, KKF, Lalla, RV, Yarom, N, Hong, C, Logan, RM, Bowen, J, Gibson, R, Saunders, DP, Zadik, Y, Ariyawardana, A, Correa, ME, Ranna, V, Bossi, P, Arany, P, Al-Azri, AR, Blijlevens, N, Hovan, A, Fregnani, E, Fulton, J, Gueiros, LA, Rouleau, T, Coller, JK, Al-Dasooqi, N, Wardill, H, Ameringer, S, Antunes, HS, Bateman, EH, Bektas, K, Bensadoun, RJ, Ten Bohmer, K, Brito-Dellan, N, Castillo, D, Chiang, K, de Mooij, C, Eilers, J, Epstein, J, Galiti, D, Fall-Dickson, JM, Gobbo, M, Issa Hazboun, H, Jensen, SB, Johansen, J, Joy, J, Joy, K, Kandwal, A, Kataoka, T, Keefe, D, Loprinzi, CL, Lubart, R, Skripnik Lucas, A, Majorana, A, Mayo, B, de Mooij, C, Mori, T, Nair, RG, Nasr, N, Nicolatou-Galitis, O, Ottaviani, G, Migliorati, C, Pentenero, M, Porcello, L, Peterson, D, Potting, C, Raber-Durlacher, J, van Sebille, YZA, Soga, Y, Sonis, S, Stringer, AM, Thorpe, D, Tilly, V, Tissing, W, Toro, JJ, Treister, NS, Vaddi, A, Weikel, D, van de Wetering, M & Zur, E 2020, 'MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy', Cancer, vol. 126, no. 19, pp. 4423-4431. https://doi.org/10.1002/cncr.33100

TY - JOUR

T1 - MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy

AU - Elad, Sharon

AU - Cheng, Karis Kin Fong

AU - Lalla, Rajesh V.

AU - Yarom, Noam

AU - Hong, Catherine

AU - Logan, Richard M.

AU - Bowen, Joanne

AU - Gibson, Rachel

AU - Saunders, Deborah P.

AU - Zadik, Yehuda

AU - Ariyawardana, Anura

AU - Correa, Maria Elvira

AU - Ranna, Vinisha

AU - Bossi, Paolo

AU - Arany, Praveen

AU - Al-Azri, Abdul Rahman

AU - Blijlevens, Nicole

AU - Hovan, Allan

AU - Fregnani, Eduardo

AU - Fulton, Janet

AU - Gueiros, Luiz Alcino

AU - Rouleau, Tanya

AU - Coller, Janet K.

AU - Al-Dasooqi, Noor

AU - Wardill, Hannah

AU - Ameringer, Suzanne

AU - Antunes, Héliton Spindola

AU - Bateman, Emma H.

AU - Bektas, Kivanc

AU - Bensadoun, René Jean

AU - Ten Bohmer, K.

AU - Brito-Dellan, Norman

AU - Castillo, Daniel

AU - Chiang, Karen

AU - de Mooij, Charlotte

AU - Eilers, June

AU - Epstein, Joel

AU - Galiti, Dimitra

AU - Fall-Dickson, Jane M.

AU - Gobbo, Margherita

AU - Issa Hazboun, Hanan

AU - Jensen, Siri Beier

AU - Johansen, Jorgen

AU - Joy, Jamie

AU - Joy, K.

AU - Kandwal, Abhishek

AU - Kataoka, Tomoko

AU - Keefe, Dorothy

AU - Loprinzi, Charles L.

AU - Lubart, Rachel

AU - Skripnik Lucas, Anna

AU - Majorana, Alessandra

AU - Mayo, Bronwen

AU - de Mooij, Charlotte

AU - Mori, Takehiko

AU - Nair, Raj G.

AU - Nasr, Narmin

AU - Nicolatou-Galitis, Ourania

AU - Ottaviani, Giulia

AU - Migliorati, Cesar

AU - Pentenero, Monica

AU - Porcello, Lorraine

AU - Peterson, Douglas

AU - Potting, Carin

AU - Raber-Durlacher, Judith

AU - van Sebille, Ysabella Z.A.

AU - Soga, Yoshihiko

AU - Sonis, Stephen

AU - Stringer, Andrea M.

AU - Thorpe, Daniel

AU - Tilly, Vanessa

AU - Tissing, Wim

AU - Toro, Juan J.

AU - Treister, Nathaniel Simon

AU - Vaddi, Anusha

AU - Weikel, Dianna

AU - van de Wetering, Marianne

AU - Zur, Eyal

PY - 2020/10/1

Y1 - 2020/10/1

N2 - Background: Mucositis is a significant toxicity of cancer therapy with numerous systemic sequelae. The goal of this systematic review was to update the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO) Clinical Practice Guidelines for the management of mucositis. Methods: The literature was reviewed systematically to identify interventions for mucositis. Studies were rated according to the presence of major and minor flaws according to previously published criteria. The body of evidence for each intervention and in each treatment setting was assigned a level of evidence based on previously published criteria. Guidelines were developed based on the level of evidence, with 3 possible guideline determinations: recommendation, suggestion, or no guideline possible. Results: The guideline covers evidence from 1197 publications related to oral or gastrointestinal mucositis. Thirteen new guidelines were developed for or against the use of various interventions in specific treatment settings, and 11 previous guidelines were confirmed after aa review of new evidence. Thirteen previously established guidelines were carried over because there was no new evidence for these interventions. Conclusions: The updated MASCC/ISOO Clinical Practice Guidelines for mucositis provide professional health caregivers with a clinical setting-specific, evidence-based tool to help with the management of mucositis in patients who have cancer.

AB - Background: Mucositis is a significant toxicity of cancer therapy with numerous systemic sequelae. The goal of this systematic review was to update the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO) Clinical Practice Guidelines for the management of mucositis. Methods: The literature was reviewed systematically to identify interventions for mucositis. Studies were rated according to the presence of major and minor flaws according to previously published criteria. The body of evidence for each intervention and in each treatment setting was assigned a level of evidence based on previously published criteria. Guidelines were developed based on the level of evidence, with 3 possible guideline determinations: recommendation, suggestion, or no guideline possible. Results: The guideline covers evidence from 1197 publications related to oral or gastrointestinal mucositis. Thirteen new guidelines were developed for or against the use of various interventions in specific treatment settings, and 11 previous guidelines were confirmed after aa review of new evidence. Thirteen previously established guidelines were carried over because there was no new evidence for these interventions. Conclusions: The updated MASCC/ISOO Clinical Practice Guidelines for mucositis provide professional health caregivers with a clinical setting-specific, evidence-based tool to help with the management of mucositis in patients who have cancer.

KW - Multinational Association of Supportive Care in Cancer and International Society for Oral Oncology (MASCC/ISOO)

KW - cancer

KW - gastrointestinal

KW - guidelines

KW - mucositis

KW - oral

UR - https://www.scopus.com/pages/publications/85088579802

U2 - 10.1002/cncr.33100

DO - 10.1002/cncr.33100

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 32786044

AN - SCOPUS:85088579802

SN - 0008-543X

VL - 126

SP - 4423

EP - 4431

JO - Cancer

JF - Cancer

IS - 19

ER -

MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy

Abstract

Bibliographical note

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this